Petasites hybridus: evidence 1A on migraine prophylaxis

Petasites hybridus extract is part of the therapeutic arsenal for migraine prophylaxis. In this commentary, we discuss the study by Lipton et al. (2004), published in Neurology, which presents a high-quality clinical trial demonstrating the efficacy of Petasites hybridus for migraine prevention. The study, conducted by renowned researchers, classifies Petasites hybridus as a Level A treatment (established efficacy based on >2 Class I trials). Despite this strong evidence, questions often arise regarding the appropriate clinical scenarios for prescribing this medication. In addition to analyzing the findings of this seminal study, this commentary explores potential indications for Petasites hybridus in clinical practice.